Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APYX 
Apyx Medical Inc (APYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: APYX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.09% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.42M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 3 | Beta 1.43 | 52 Weeks Range 0.76 - 2.73 | Updated Date 09/15/2025 |
52 Weeks Range 0.76 - 2.73 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.11% | Operating Margin (TTM) -22.63% |
Management Effectiveness
Return on Assets (TTM) -12.45% | Return on Equity (TTM) -154.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 89197903 | Price to Sales(TTM) 1.71 |
Enterprise Value 89197903 | Price to Sales(TTM) 1.71 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA -5.33 | Shares Outstanding 37819500 | Shares Floating 25697579 |
Shares Outstanding 37819500 | Shares Floating 25697579 | ||
Percent Insiders 14.55 | Percent Institutions 43.29 |
Upturn AI SWOT
Apyx Medical Inc
Company Overview
History and Background
Apyx Medical, Inc. (formerly Bovie Medical Corporation) was founded in 1921. It initially focused on electrosurgical instruments and has evolved to concentrate on energy-based technologies for cosmetic and surgical markets, primarily utilizing its Renuvionu00ae technology.
Core Business Areas
- Surgical: Develops, manufactures, and markets energy-based surgical products utilizing its Helium Plasma Technology (HPT), primarily the Renuvionu00ae system. These products are used in a variety of surgical procedures.
- Cosmetic: The Renuvionu00ae system is also marketed for cosmetic procedures, focusing on skin rejuvenation and tightening.
Leadership and Structure
Apyx Medical is led by a Chief Executive Officer and has a structured organizational hierarchy with departments covering sales, marketing, R&D, operations, and finance.
Top Products and Market Share
Key Offerings
- Renuvionu00ae: Renuvionu00ae is Apyx Medical's flagship product. It uses helium plasma technology for subdermal coagulation. Market share data is not readily available for this specific technology, but Apyx is a smaller player in the broader energy-based surgical device market. Competitors include Johnson & Johnson (Ethicon), Medtronic, and Bausch Health (Solta Medical).
Market Dynamics
Industry Overview
The medical device industry, specifically the segment focused on energy-based surgical devices, is growing due to an aging population, increasing demand for minimally invasive procedures, and technological advancements.
Positioning
Apyx Medical positions itself as an innovator in the energy-based surgical device market, particularly with its Renuvionu00ae technology. Its competitive advantage lies in the unique application of helium plasma technology.
Total Addressable Market (TAM)
The total addressable market for energy-based surgical devices is estimated in the billions of USD annually. Apyx Medical, as a smaller player, is positioned to capture a share of this market through focused marketing and product development. The TAM changes based on procedures done by doctors and the equipment needed.
Upturn SWOT Analysis
Strengths
- Innovative Technology (Renuvionu00ae)
- Focus on Minimally Invasive Procedures
- Strong Brand Recognition within Specific Niches
Weaknesses
- Limited Market Share Compared to Larger Competitors
- Dependence on a Single Core Technology
- Regulatory Hurdles and Clinical Trial Requirements
- Reliance on Renuvion as its core business driver
Opportunities
- Expansion into New Geographic Markets
- Development of New Applications for Renuvionu00ae
- Partnerships with Medical Professionals and Institutions
- Increased Adoption of Minimally Invasive Procedures
Threats
- Competition from Established Medical Device Companies
- Technological Advancements by Competitors
- Changes in Healthcare Regulations and Reimbursement Policies
- Product Liability Risks
Competitors and Market Share
Key Competitors
- JNJ
- MDT
- ZBH
- BSX
Competitive Landscape
Apyx Medical faces stiff competition from larger, more established medical device companies. Its advantages include innovative technology and a focus on minimally invasive procedures, while its disadvantages include limited market share and dependence on a single core product.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on product adoption and sales performance over the years.
Future Projections: Future projections are based on analyst estimates and company guidance. Analysts forecast growth but should be looked at with caution due to external factors and changes.
Recent Initiatives: Recent initiatives may include new product launches, marketing campaigns, or strategic partnerships.
Summary
Apyx Medical demonstrates innovation with its Renuvion technology. The company's potential is limited by high competition from larger companies, which the company needs to overcome. Renuvion's sales are promising, but dependence can be risky. Expansion and diversification could solidify Apyx Medical's market position. Regulatory approvals remain a crucial aspect to monitor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apyx Medical Inc
Exchange NASDAQ | Headquaters Clearwater, FL, United States | ||
IPO Launch date 1987-01-01 | President, CEO & Director Mr. Charles D. Goodwin II | ||
Sector Healthcare | Industry Medical Devices | Full time employees 220 | Website https://apyxmedical.com |
Full time employees 220 | Website https://apyxmedical.com | ||
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.